Imagine a world where children are protected from painful illnesses caused by the chikungunya virus. This virus can lead to debilitating symptoms like fever and joint pain, making it tough for kids to enjoy their daily activities. In a new study, a vaccine designed to fight this virus is being tested in children aged 1 to under 12 years. The goal is to see if the vaccine is safe and effective at helping their bodies build defenses against chikungunya. Researchers will track any side effects and measure how well the vaccine works after administration. If successful, this vaccine could mean fewer hospital visits and healthier kids, giving families peace of mind. However, it's important to remember that this is still in the testing phase. While the potential is exciting, we need to wait for the results before we can celebrate a new tool in protecting our children from chikungunya.
Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in ChildrenCould a New Vaccine Protect Children from Chikungunya Virus?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Monitor for updates on CHIKV VLP vaccine's safety and immunogenicity in children.
This ongoing Phase 3 trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the safety and immunogenicity of the CHIKV VLP vaccine in children aged 1 to <12 years. The study aims to enroll 720 participants and is sponsored by Bavarian Nordic. The primary immunogenicity endpoint is the seroresponse rate on Day 22 in seronegative children, while safety endpoints include the incidence of adverse events of special interest (AESI), medically attended adverse events (MAAEs), and serious adverse events (SAEs). Additionally, the study monitors unsolicited adverse events through Day 29. The trial's primary completion is anticipated by December 2028. The results will provide critical insights into the vaccine's potential to protect children against the chikungunya virus, with safety and immunogenicity being key measures of success.
What this means for you:
A new vaccine could be a game-changer in protecting children from chikungunya virus and its painful effects. More on Chikungunya
Narrative review discusses Chikungunya virus infection without reporting specific clinical data or outcomes
Chikungunya May Become Chronic Due to Immune System Mistake
This source is a narrative review focusing on Chikungunya virus infection.
Chikungunya can trigger a chain reaction in the immune system that leads to chronic joint pain, new research shows.
Environmental and social factors influence arbovirus proliferation in changing climate conditions
Rising Temperatures Push Dangerous Viruses Into New Communities
This review examines how environmental and social factors, including increasing temperatures and urbanization, affect the proliferation of a…
Warming weather pushes dangerous insect-borne viruses into new areas, making early warning systems and vaccines more critical than ever for …
Observational study evaluates clinical prediction models for dengue, chikungunya, and Oropouche fever in Brazil
New Tool Helps Doctors Tell Dengue, Chikungunya, and Oropouche Fever Apart
This observational study analyzed surveillance data from Espirito Santo state, Brazil, involving 465,280 observations to assess clinical pre…
A new online tool can tell apart dengue, chikungunya, and Oropouche fever using simple symptoms, helping doctors make faster, more accurate …
Meta-analysis of maternal Chikungunya infection and pregnancy outcomes
Chikungunya in Pregnancy: When Timing Changes Everything
This meta-analysis of 57 observational studies synthesized data on maternal Chikungunya virus infection during pregnancy.
This study reveals when during pregnancy chikungunya poses the greatest danger — and it’s later than we thought.
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE3
Condition(s): Chikungunya Virus
Intervention(s): CHIKV VLP vaccine (BIOLOGICAL), Placebo (BIOLOGICAL)
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.
Primary Outcome(s): Safety Endpoint 3: Incidence of AESI, MAAEs, and SAEs; Primary Immunogenicity Endpoint: Day 22 anti-CHIKV SNA seroresponse rate in seronegative children; Safety Endpoint 2: Incidence of unsolicited AEs through Day 29
Enrollment: 720 (ESTIMATED)
Lead Sponsor: Bavarian Nordic
Start: 2025-06-05 | Primary Completion: 2028-12
Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks
New Drug Lowers Sugar and Shrinks Weight in Diabetes
Related in Drug Pipeline
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.